Flash Sell! Grab a Double-Digit Gain on This Biotech

By Ray BlancoPosted August 13, 2018

We have new quarterly results from biotech companies, news of a clinical trial from an Alzheimer’s play, and analysis on the success of our latest pick. Ray has plenty of updates this week to keep your portfolio thriving…

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!

Breakthrough Technology Alert

This is the best time to be investing in world-changing technologies, as unprecedented innovations are taking off right now… Breakthrough Technology Alert tirelessly researches these exciting new breakthrough technologies to keep you well informed, outline specific opportunities, and keep you ahead of the game.

Ray Blanco

After earning a bachelor’s degree in information technology from Hodges University, Ray Blanco spent over a decade working for public and private companies as a network technician and systems analyst. Ray used to work for one of the most successful private wealth management firms in the country — with over $30 billion in assets under...

View More By Ray Blanco

Arrowhead Grabs Huge RNAi IP, NanoViricides Begins to Get Recognition

By Patrick CoxPosted October 25, 2011

Dear Breakthrough Technology Alert Reader, It’s cooling down in South Florida. The windows are open, and the weather’s perfect for longboard land paddling, which is the core of my exercise regimen these days. This is, however, going to be a difficult month for me. I’ve just been told by the Agora Financial brass that I...

Crucial News From Neuralstem, Star Scientific and Galectin Therapeutics

By Patrick CoxPosted September 18, 2012

The action in our core portfolio continues to accelerate. There's so much news, in fact, that I'm having a hard time keeping up. I meant to update you today on Protext Mobility (NASDAQ: TXTM) and NanoViricides (OTCBB: NNVC), as I've spoken with both CEOs about recent developments. Though they are extremely positive, I'm going to put both updates off until the next alert. Not only have we just finished your next monthly issue, but I'm working on the video interview with ChromaDex CEO Frank Jaksch regarding the next generation of dietary supplements. Jaksch is the most-informed person on this issue, and I look forward to having it for you. I think the benefits will be therapeutic as well as financial.

Inovio Reports Successful Phase I Long-Term Cervical DNA Vaccine Data

By Patrick CoxPosted May 10, 2011

It was just released that Inovio cervical cancer vaccine is effective in more than two thirds of women who were treated. Also, updates on BioTime and BioMimetic.

Ask Stephen About These Biotech Stocks

By Stephen PetranekPosted April 20, 2015

I’ve been getting some interesting questions from readers via the AskStephen service I established a month ago, so allow me to share some of the best inquiries and offer my thoughts.

Excellent News From Our Biotech Companies

By Ray BlancoPosted October 8, 2013

One of our pharmaceutical companies has unveiled further data from its completed Phase 2 trial in melanoma at the European Cancer Congress 2013. If you recall, this company’s cancer compound, PV-10, is derived from a rose-colored chemical dye first synthesized in 1882.

Tax Selling Time Creates Even Greater Opportunities for Transformational Investors

By Patrick CoxPosted December 17, 2012

I'm traveling as you read this, which means I wrote this more than a few days ago. This makes me a little uncomfortable because there are major events breaking on a regular basis that I may not be able to write about in this issue.